HHS temporarily eases compounding restrictions for six unapproved peptides

Under a temporary HHS policy, STAT reports, the agency will not take action against eligible state-licensed pharmacies, federal facilities or licensed physicians compounding six peptides while the FDA weighs pharmacy compounding. Scientific American reports that recipients need valid prescriptions and the peptides must be made by registered manufacturers. The six are not FDA-approved medicines, and evidence for their touted benefits is often scant, the outlet says.